NASDAQ:ENDP - Endo International Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.92 -0.20 (-3.27 %) (As of 05/24/2019 04:00 PM ET)Previous Close$6.12Today's Range$5.80 - $6.1852-Week Range$5.96 - $18.50Volume146,587 shsAverage Volume3.28 million shsMarket Capitalization$1.34 billionP/E Ratio2.06Dividend YieldN/ABeta1.12 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. Receive ENDP News and Ratings via Email Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:ENDP Previous Symbol CUSIP29264F20 CIK1593034 Webhttp://www.endo.com/ Phone011-353-1268-2000Debt Debt-to-Equity RatioN/A Current Ratio1.30 Quick Ratio1.11Price-To-Earnings Trailing P/E Ratio2.06 Forward P/E Ratio2.73 P/E GrowthN/A Sales & Book Value Annual Sales$2.95 billion Price / Sales0.45 Cash Flow$5.8039 per share Price / Cash Flow1.02 Book Value($2.19) per share Price / Book-2.70Profitability EPS (Most Recent Fiscal Year)$2.89 Net Income$-1,031,470,000.00 Net Margins-18.35% Return on Equity-199.18% Return on Assets6.14%Miscellaneous Employees2,910 Outstanding Shares226,182,000Market Cap$1.34 billion Next Earnings Date8/14/2019 (Estimated) OptionableOptionable Endo International (NASDAQ:ENDP) Frequently Asked Questions What is Endo International's stock symbol? Endo International trades on the NASDAQ under the ticker symbol "ENDP." How were Endo International's earnings last quarter? Endo International PLC (NASDAQ:ENDP) announced its quarterly earnings results on Thursday, May, 9th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.42 by $0.11. The company had revenue of $720 million for the quarter, compared to analyst estimates of $692.31 million. Endo International had a negative net margin of 18.35% and a negative return on equity of 199.18%. Endo International's revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.67 earnings per share. View Endo International's Earnings History. When is Endo International's next earnings date? Endo International is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Endo International. What guidance has Endo International issued on next quarter's earnings? Endo International issued an update on its FY19 earnings guidance on Thursday, May, 9th. The company provided earnings per share guidance of $2.00-2.25 for the period, compared to the Thomson Reuters consensus estimate of $2.17. The company issued revenue guidance of $2.76-2.96 billion, compared to the consensus revenue estimate of $2.87 billion.Endo International also updated its FY 2019 guidance to $2.00-2.25 EPS. What price target have analysts set for ENDP? 18 brokers have issued 1-year price targets for Endo International's stock. Their forecasts range from $9.00 to $26.00. On average, they expect Endo International's share price to reach $15.1333 in the next twelve months. This suggests a possible upside of 156.1% from the stock's current price. View Analyst Price Targets for Endo International. What is the consensus analysts' recommendation for Endo International? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 1 sell rating, 11 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endo International. Has Endo International been receiving favorable news coverage? News articles about ENDP stock have been trending negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Endo International earned a daily sentiment score of -2.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. Who are some of Endo International's key competitors? Some companies that are related to Endo International include Amarin (AMRN), GW Pharmaceuticals PLC- (GWPH), Ascendis Pharma A/S (ASND), Horizon Therapeutics (HZNP), American Brivision (Holding) (ABVC), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Blueprint Medicines (BPMC), United Therapeutics (UTHR), Evotec (EVTCY), ACADIA Pharmaceuticals (ACAD), HUTCHISON CHINA/S (HCM), Global Blood Therapeutics (GBT) and Ultragenyx Pharmaceutical (RARE). What other stocks do shareholders of Endo International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Endo International investors own include Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Gilead Sciences (GILD), General Electric (GE), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), NVIDIA (NVDA), Bank of America (BAC) and Twitter (TWTR). Who are Endo International's key executives? Endo International's management team includes the folowing people: Mr. Paul V. Campanelli, Pres, CEO & Director (Age 57)Mr. Blaise Coleman, Exec. VP & CFO (Age 45)Mr. Terrance J. Coughlin, Exec. VP & COO (Age 53)Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 47)Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 62) Who are Endo International's major shareholders? Endo International's stock is owned by a number of of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (1.18%), Connor Clark & Lunn Investment Management Ltd. (0.84%), Diamond Hill Capital Management Inc. (0.60%), Acadian Asset Management LLC (0.34%), Rhumbline Advisers (0.23%) and Parametric Portfolio Associates LLC (0.19%). Company insiders that own Endo International stock include Blaise Coleman, Matthew Joseph Maletta, Nancy J Hutson, Paul Campanelli, Roger H Kimmel, Terrance J Coughlin and William P Montague. View Institutional Ownership Trends for Endo International. Which major investors are selling Endo International stock? ENDP stock was sold by a variety of institutional investors in the last quarter, including Pinebridge Investments L.P., Parametric Portfolio Associates LLC, Meeder Asset Management Inc., Gabelli Funds LLC, O Shaughnessy Asset Management LLC, California State Teachers Retirement System, American International Group Inc. and Globeflex Capital L P. Company insiders that have sold Endo International company stock in the last year include Nancy J Hutson, Roger H Kimmel and William P Montague. View Insider Buying and Selling for Endo International. Which major investors are buying Endo International stock? ENDP stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., Geode Capital Management LLC, Tibra Equities Europe Ltd, Nordea Investment Management AB, BNP Paribas Arbitrage SA, Diamond Hill Capital Management Inc. and Factorial Partners LLC. Company insiders that have bought Endo International stock in the last two years include Blaise Coleman, Matthew Joseph Maletta, Paul Campanelli and Terrance J Coughlin. View Insider Buying and Selling for Endo International. How do I buy shares of Endo International? Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Endo International's stock price today? One share of ENDP stock can currently be purchased for approximately $5.91. How big of a company is Endo International? Endo International has a market capitalization of $1.34 billion and generates $2.95 billion in revenue each year. The company earns $-1,031,470,000.00 in net income (profit) each year or $2.89 on an earnings per share basis. Endo International employs 2,910 workers across the globe. What is Endo International's official website? The official website for Endo International is http://www.endo.com/. How can I contact Endo International? Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected] MarketBeat Community Rating for Endo International (NASDAQ ENDP)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 860 (Vote Outperform)Underperform Votes: 721 (Vote Underperform)Total Votes: 1,581MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: Risk Tolerance Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.